Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676831 · ClinicalTrials.gov registry record · Phase 1
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
A Phase 1 study of Cutaneous T Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01676831 is a Phase 1 study of Cutaneous T Cell Lymphoma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 13 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01676831, a Phase 1 study of Cutaneous T Cell Lymphoma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to explore the safety and the preliminary efficacy of two concentrations (0.06% and 0.03%)gel that is applied to lesions of early stage (IA, IB,IIA) Cutaneous T Cell Lymphoma patients. This study is supported by grant 1R01FD004092-01A1 from the Office of Orphan Products Development, FDA.
Conditions Studied
Interventions
- DRUG Topical resiquimod 0.06%
- DRUG topical resiquimod 0.03%
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676831
The ClinicalTrials.gov registry entry for NCT01676831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (81% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Topical resiquimod 0.06% is the first listed.
NCT01676831 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01676831 about?
NCT01676831 is a clinical study titled "Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)". The objective of this study is to explore the safety and the preliminary efficacy of two concentrations (0.06% and 0.03%)gel that is applied to lesions of early stage (IA, IB,IIA) Cutaneous T Cell Lymphoma patients. This study is supported by grant 1R01FD004092-01A1 from the Office of Orphan Produc...
What is the current status of trial NCT01676831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-02. Estimated completion is 2015-09-28.
What conditions does trial NCT01676831 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.
What interventions are being tested in trial NCT01676831?
The interventions under investigation include: Topical resiquimod 0.06% (DRUG), topical resiquimod 0.03% (DRUG).
Who is sponsoring clinical trial NCT01676831?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01676831 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.